Cargando…

The Role of Chemotherapy Plus Immune Checkpoint Inhibitors in Oncogenic-Driven NSCLC: A University of California Lung Cancer Consortium Retrospective Study

INTRODUCTION: There is a paucity of data on immune checkpoint inhibitors (ICIs) plus doublet chemotherapy (C) in patients with advanced lung cancer whose tumor harbors an actionable mutation. We sought to provide insight into the role of this combination in relation to chemotherapy alone in this pat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Benjamin, David J., Chen, Shuai, Eldredge, Joanna B., Schokrpur, Shiruyeh, Li, Debory, Quan, Zhikuan, Chan, Jason W., Cummings, Amy L., Daly, Megan E., Goldman, Jonathan W., Gubens, Matthew A., Harris, Jeremy P., Onaitis, Mark W., Zhu, Viola W., Patel, Sandip P., Kelly, Karen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9679033/ https://www.ncbi.nlm.nih.gov/pubmed/36426286 http://dx.doi.org/10.1016/j.jtocrr.2022.100427

Ejemplares similares

The splicing regulatory element, UGCAUG, is phylogenetically and spatially conserved in introns that flank tissue-specific alternative exons
por: Minovitsky, Simon, et al.
Publicado: (2005)

Evidence That SOX2 Overexpression Is Oncogenic in the Lung
por: Lu, Yun, et al.
Publicado: (2010)

Induction immune-checkpoint inhibitors for resectable oncogene-mutant NSCLC: A multicenter pooled analysis
por: Zhang, Chao, et al.
Publicado: (2022)

MicroRNAs miR-146a/b negatively modulate the senescence-associated inflammatory mediators IL-6 and IL-8
por: Bhaumik, Dipa, et al.
Publicado: (2009)

Erlotinib and Onalespib Lactate Focused on EGFR Exon 20 Insertion Non-Small Cell Lung Cancer (NSCLC): A California Cancer Consortium Phase I/II Trial (NCI 9878)
por: Riess, Jonathan W, et al.
Publicado: (2021)

Editorial: Immunotherapy for NSCLC with oncogenic driver variants
por: Du, Yijia, et al.
Publicado: (2022)

Long-Term Survivors of Pancreatic Cancer: A California Population-Based Study
por: Kardosh, Adel, et al.
Publicado: (2018)

Lymphatic-preserving treatment sequencing with immune checkpoint inhibition unleashes cDC1-dependent antitumor immunity in HNSCC
por: Saddawi-Konefka, Robert, et al.
Publicado: (2022)

CRISPR-Mediated VHL Knockout Generates an Improved Model for Metastatic Renal Cell Carcinoma
por: Schokrpur, Shiruyeh, et al.
Publicado: (2016)

Commentary: Stereotactic body radiation therapy versus surgery for stage I non–small cell lung cancer in healthy patients: Not quite there yet
por: Sideris, Antonios, et al.
Publicado: (2022)

Phase 1 Study of Ceritinib Combined With Trametinib in Patients With Advanced ALK- or ROS1-Positive NSCLC
por: Lara, Matthew S., et al.
Publicado: (2022)

The Border Health Consortium of the Californias—Forming a Binational (California–Baja California) Entity to Address the Health of a Border Region: A Case Study
por: Kozo, Justine, et al.
Publicado: (2018)

A Non-integrating Lentiviral Approach Overcomes Cas9-Induced Immune Rejection to Establish an Immunocompetent Metastatic Renal Cancer Model
por: Hu, Junhui, et al.
Publicado: (2018)

Hyperprogressive NSCLC With Two Immune-Checkpoint Inhibitors
por: Kasparian, Saro, et al.
Publicado: (2020)

circ_0005962 functions as an oncogene to aggravate NSCLC progression
por: Zhang, Zhihong, et al.
Publicado: (2021)

Overcoming MET-mediated resistance in oncogene-driven NSCLC
por: Reischmann, Nadine, et al.
Publicado: (2023)

Cell of origin of lung cancer
por: Hanna, Jennifer M., et al.
Publicado: (2013)

Catalog of 5′ fusion partners in RET+ NSCLC Circa 2020
por: Ou, Sai-Hong Ignatius, et al.
Publicado: (2020)

Spotlight on Mobocertinib (TAK-788) in NSCLC with EGFR Exon 20 Insertion Mutations
por: Zhang, Shannon S, et al.
Publicado: (2021)

THE LONGEVITY CONSORTIUM VISION
por: Evans, Daniel S, et al.
Publicado: (2019)

The Southern California Extracorporeal Membrane Oxygenation Consortium During the Coronavirus Disease 2019 Pandemic
por: Odish, Mazen, et al.
Publicado: (2021)

TdIF1: a putative oncogene in NSCLC tumor progression
por: Zhang, Yujuan, et al.
Publicado: (2018)

EVI5 is an oncogene that regulates the proliferation and metastasis of NSCLC cells
por: Cai, Tingting, et al.
Publicado: (2020)

ESMO20 YO for YO: highlights on oncogene-addicted NSCLC
por: Lim, K.H.J., et al.
Publicado: (2020)

Pretreatment Lung Function and Checkpoint Inhibitor Pneumonitis in NSCLC
por: Reuss, Joshua E., et al.
Publicado: (2021)

Adjuvant and neoadjuvant use of immune checkpoint inhibitors in NSCLC
por: Walia, Anushka, et al.
Publicado: (2023)

Osimertinib in NSCLC With Atypical EGFR-Activating Mutations: A Retrospective Multicenter Study
por: Ji, Jingran, et al.
Publicado: (2023)

Immune checkpoint inhibitor treatment in patients with oncogene-addicted non-small cell lung cancer (NSCLC): summary of a multidisciplinary round-table discussion
por: Berghoff, Anna S., et al.
Publicado: (2019)

USP17 is required for trafficking and oncogenic signaling of mutant EGFR in NSCLC cells
por: McCann, Aidan P., et al.
Publicado: (2018)

Catalog of 5’ Fusion Partners in ALK-positive NSCLC Circa 2020
por: Ou, Sai-Hong Ignatius, et al.
Publicado: (2020)

1571P COVID-19 positivity rates in patients with an active cancer diagnosis in the University of California Cancer Consortium
por: Hong, J., et al.
Publicado: (2021)

Choosing the best first-line therapy: NSCLC with no actionable oncogenic driver
por: Kim, So Yeon, et al.
Publicado: (2020)

The Strategies and Mechanisms of Immune Checkpoint Inhibitors for Brain Metastases in NSCLC
por: Li, Ji, et al.
Publicado: (2022)

Biodegradation of thiocyanate by a native groundwater microbial consortium
por: Spurr, Liam P., et al.
Publicado: (2019)

Role of Radiosurgery and Stereotactic Ablative Radiotherapy for Oligometastatic Non-Oncogene Addicted NSCLC
por: Badellino, Serena, et al.
Publicado: (2022)

Use of liquid biopsy in monitoring therapeutic resistance in EGFR oncogene addicted NSCLC
por: Iacovino, Marialucia, et al.
Publicado: (2020)

Immune Checkpoint Inhibitors and Radiotherapy in NSCLC Patients: Not Just a Fluke
por: Belluomini, Lorenzo, et al.
Publicado: (2019)

Immune-Checkpoint Inhibitors Combinations in Metastatic NSCLC: New Options on the Horizon?
por: Passiglia, Francesco, et al.
Publicado: (2021)

Combining STAT3-Targeting Agents with Immune Checkpoint Inhibitors in NSCLC
por: Papavassiliou, Kostas A., et al.
Publicado: (2023)

Immune Checkpoint Inhibitors in “Special” NSCLC Populations: A Viable Approach?
por: Bronte, Giuseppe, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_l9h42091kahaqln4303ss6vkvc